Skip to main content
Amber Foust on Muck Rack

Amber Foust

As seen in: The BMJ
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Amber

Contact Amber, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

429 Point of care (POC) manufacturing with warm chain production allows for higher immune cell recovery and fitness for cancer therapeutic applications | Journal for ImmunoTherapy of Cancer

|
By Brent Dixon, John Powderly, Amber Foust, Renaud F Warin
| The BMJ Verified
Abstract Background While Chimeric Antigen Receptor (CAR) technology has shown promises, FDA commercially approved applications are not yet approved for solid tumors. This could be related to a traditional centralized cold-chain manufacturing process, with multiple freeze/thaw cycles and transport, that ultimately produces substandard effector cells at a much higher cost, while increasing patient wait time (figure 1).
Open in Who Shared Issue with article?
See all 1 articles